Subscribe to RSS
DOI: 10.1160/TH08-10-0665
The tumour necrosis factor superfamily ligand APRIL (TNFSF13) is released upon platelet activation and expressed in atherosclerosis
Financial support: This work was supported by grants from the Norwegian Council of Cardiovascular Research, Research Council of Norway, University of Oslo, Medinnova Foundation, Helse Sør, Rikshospitalet, and the Swedish Research Council.Publication History
Received:
13 October 2008
Accepted after major revision:
23 June 2009
Publication Date:
24 November 2017 (online)
Summary
Activated platelets release a wide range of inflammatory mediators, including members of the tumour necrosis factor (TNF) superfamily (e.g. CD40 ligand [CD40L] and LIGHT). Such platelet-mediated inflammation could be involved in atherogenesis and plaque destabilisation. In the present study we investigated whether APRIL, another member of the TNF superfamily that has been detected in megakaryocytes, could be released from platelets upon activation. The release of APRIL was studied in thrombin receptor (SFLLRN) activated platelets, and the expression of APRIL was examined in plasma and within the atherosclerotic lesion in patients with carotid and coronary atherosclerosis. Upon SFLLRN activation, there was a gradual release of APRIL, reaching maximum after 90 minutes. While this pattern is similar to that of CD40L and LIGHT, the release of APRIL was quite differently regulated. Thus, prostaglandin E1,but not inhibitors of metal-dependent proteases and actin polymerisation or the lack of GP IIb/IIIa, blocks APRIL release in activated platelets. With relevance to atherogenesis, we found that patients with coronary artery disease (n=80) had raised plasma levels of APRIL as compared with controls (n=20), and APRIL immunoreactivity was detected in aggregated platelets within the ruptured plaque in patients with myocardial infarction and within macrophages in symptomatic carotid plaques. In conclusion, activated platelets release significant amounts of APRIL in a longlasting manner, differently regulated than the gradual release of other platelet-derived TNF superfamily ligands. The enhanced expression of APRIL in atherosclerotic disorders, both systemically and within the lesion, may suggest a potential involvement of APRIL in atherogenesis.
-
References
- 1 Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-3384.
- 2 Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 2005; 96: 612-616.
- 3 Huo Y, Schober A, Forlow SB. et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 09: 61-67.
- 4 Massberg S, Brand K, Gruner S. et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196: 887-896.
- 5 May AE, Seizer P, Gawaz M. Platelets: inflammatory firebugs of vascular walls. Arterioscler Thromb Vasc Biol 2008; 28: s5-10.
- 6 Langer HF, Gawaz M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost 2008; 99: 480-486.
- 7 Schonbeck U, Libby P. The CD40/CD154 receptor/ ligand dyad. Cell Mol Life Sci 2001; 58: 4-43.
- 8 Otterdal K, Smith C, Oie E. et al. Platelet-derived LIGHT induces inflammatory responses in endothelial cells and monocytes. Blood 2006; 108: 928-935.
- 9 Celik S, Langer H, Stellos K. et al. Platelet-associated LIGHT (TNFSF14) mediates adhesion of platelets to human vascular endothelium. Thromb Haemost 2007; 98: 798-805.
- 10 Gross JA, Johnston J, Mudri S. et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 995-999.
- 11 Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 2005; 17: 282-289.
- 12 Dillon SR, Gross JA, Ansell SM. et al. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006; 05: 235-246.
- 13 Bonci D, Hahne M, Felli N. et al. Potential role of APRIL as autocrine growth factor for megakaryocytopoiesis. Blood 2004; 104: 3169-3172.
- 14 Otterdal K, Pedersen TM, Solum NO. Release of soluble CD40 ligand after platelet activation: studies on the solubilization phase. Thromb Res 2004; 114: 167-177.
- 15 Olofsson PS, Jatta K, Wagsater D. et al. The antiviral cytomegalovirus inducible gene 5/viperin is expressed in atherosclerosis and regulated by proinflammatory agents. Arterioscler Thromb Vasc Biol 2005; 25: e113-116.
- 16 Lopez-Fraga M, Fernandez R, Albar JP. et al. Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep 2001; 02: 945-951.
- 17 Macaulay IC, Carr P, Gusnanto A. et al. Platelet genomics and proteomics in human health and disease. J Clin Invest 2005; 115: 3370-3377.
- 18 Gnatenko DV, Zhu W, Bahou WF. Multiplexed genetic profiling of human blood platelets using fluorescent microspheres. Thromb Haemost 2008; 100: 929-936.
- 19 van Gils JM, da Costa Martins PA, Mol A. et al. Transendothelial migration drives dissociation of plateletmonocyte complexes. Thromb Haemost 2008; 100: 271-279.
- 20 Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 2002; 22: 913-922.
- 21 von Hundelshausen P, Petersen F, Brandt E. Platelet-derived chemokines in vascular biology. Thromb Haemost 2007; 97: 704-713.
- 22 Henn V, Slupsky JR, Grafe M. et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-594.
- 23 Rosado JA, Porras T, Conde M. et al. Cyclic nucleotides modulate store-mediated calcium entry through the activation of protein-tyrosine phosphatases and altered actin polymerization in human platelets. J Biol Chem 2001; 276: 15666-15675.
- 24 Thangarajh M, Masterman T, Rot U. et al. Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis. J Neuroimmunol 2005; 167: 210-214.
- 25 Jonsson MV, Szodoray P, Jellestad S. et al. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren’s syndrome. J Clin Immunol 2005; 25: 189-201.
- 26 Koyama T, Tsukamoto H, Miyagi Y. et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 1065-1067.
- 27 Stohl W, Metyas S, Tan SM. et al. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2004; 63: 1096-1103.
- 28 Cheema GS, Roschke V, Hilbert DM. et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44: 1313-1319.
- 29 Tan SM, Xu D, Roschke V. et al. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003; 48: 982-92.